HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer
BackgroundThe expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in residual lesions may be different compared with primary tumors of the breast after neoadjuvant therapy (NAT). Given the clinical implications of hormone receptor exp...
Saved in:
| Main Authors: | Jing Wang, Xin Long, Mingxi Tang, Xiuli Xiao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1522460/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
by: Rashmi Patnayak, et al.
Published: (2015-01-01) -
Protein expression of estrogen, progesterone, and human epidermal growth factor receptors in young Iraqi women with breast cancer
by: K. A. Al-Hilali, et al.
Published: (2024-10-01) -
Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer
by: Zhengjia Lu, et al.
Published: (2025-06-01) -
Immunohistochemical Expression of ROS1 in invasive ductal carcinoma of breast in association with hormonal receptor status and Her2Neu expression
by: Muhammad Umair, et al.
Published: (2024-10-01) -
Receptor Status Differences in Prognosis for Breast Cancer
by: Yelda Deligöz Bildacı, et al.
Published: (2024-07-01)